Thesan Pharmaceuticals Raises $16M

San Diego-based Thesan Pharmaceuticals said today that it has raised $16M in a Series A round, for the firm's developing of treatments for dermatological disorders. The firm said the funding was co-led by Novo Ventures and Novartis Venture Funds. Thesan is headed by Gordon Foulkes, and said it has licensed its products from the University of California, Irvine, out of the laboratory of Professor Daniele Piomelli, who is Louise Turner Arnold Chair of Neurosciences at UCI. Foulkes is the former CEO of Excaliard Pharmaceuticals (acquired by Pfizer) and also served at RiverVest Ventures. More information »